Immune Cells as Trojan Horses for Cancer Nanotherapy
Source abstract
Abstract
High Resolution Image Download MS PowerPoint Slide Nanotechnology is a promising strategy in the fight against cancer by leveraging the unique properties of nanomaterials for targeted drug delivery. A significant challenge in this domain is overcoming biological barriers and ensuring precise delivery to tumor sites. Immune cells, inherently adept at navigating the body’s defense systems and homing to tumor sites, present an excellent solution as Trojan horses for cancer nanotherapy. This review explores the utilization of immune cells as carriers or mediators of nanoparticle-based therapeutics. The Trojan horse strategy is presented in the context of nanomedicine and cancer, followed by a discussion of its advantages. Next, the diversity of nanoparticle systems that have shown positive therapeutic outcomes in preclinical studies is explored. The challenges of using immune cells as Trojan horses, such as nanoparticle loading and manipulation, are analyzed. Finally, strategies for fine-tuning nanoparticles to design an effective Trojan horse approach are suggested. By synthesizing current research findings, this review underscores the potential of nanotechnology in combination with immune cells for innovative and effective cancer treatments.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Phagocytosis and Immune Regulation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemical and Biological Sciences, Universidad de las Américas Puebla, ExHda. De Sta. Catarina Mártir s/n, 72810 Cholula, Puebla, México
Swiss Federal Laboratories for Materials Science and Technology (Empa)
Funding
Consejo Nacional de Ciencia y Tecnolog??a · Universidad de las Am??ricas Puebla
References (100+)
Show source-provided references
1. 10.15226/2374-6866/1/1/0010910.15226/2374-6866/1/1/00109 ↗
2. Pillai G. · 2019 · 22110.1016/B978-0-12-814029-1.00009-0 ↗
3. 10.1186/s40169-017-0175-010.1186/s40169-017-0175-0 ↗
4. 10.1016/j.ddtec.2011.11.01010.1016/j.ddtec.2011.11.010 ↗
5. 10.3390/jpm1106057110.3390/jpm11060571 ↗
6. 10.1016/j.bioactmat.2023.12.02710.1016/j.bioactmat.2023.12.027 ↗
7. 10.1155/2014/78906910.1155/2014/789069 ↗
8. 10.1002/adfm.20210008810.1002/adfm.202100088 ↗
9. 10.1371/journal.ppat.100843410.1371/journal.ppat.1008434 ↗
10. 10.1016/j.jconrel.2020.07.04310.1016/j.jconrel.2020.07.043 ↗
11. 10.1016/j.apsb.2021.02.01910.1016/j.apsb.2021.02.019 ↗
12. 10.3389/fimmu.2020.60794510.3389/fimmu.2020.607945 ↗
13. 10.1080/10717544.2019.170114110.1080/10717544.2019.1701141 ↗
14. 10.1186/s12951-024-02397-510.1186/s12951-024-02397-5 ↗
15. 10.1021/nl072209h10.1021/nl072209h ↗
16. 10.1007/s12645-012-0029-910.1007/s12645-012-0029-9 ↗
17. 10.1021/jacs.9b0462110.1021/jacs.9b04621 ↗
18. 10.2217/nnm-2020-010610.2217/nnm-2020-0106 ↗
19. 10.1126/sciadv.aay160110.1126/sciadv.aay1601 ↗
20. 10.1136/jitc-2021-00250810.1136/jitc-2021-002508 ↗
21. 10.1016/j.cell.2020.09.05910.1016/j.cell.2020.09.059 ↗
22. 10.1038/s41467-019-11911-510.1038/s41467-019-11911-5 ↗
23. 10.1002/adhm.20150099810.1002/adhm.201500998 ↗
24. 10.1038/s41467-017-01830-810.1038/s41467-017-01830-8 ↗
25. 10.1007/s13346-023-01413-910.1007/s13346-023-01413-9 ↗
26. 10.1038/nnano.2017.5710.1038/nnano.2017.57 ↗
27. 10.1136/jitc-2022-00591610.1136/jitc-2022-005916 ↗
28. 10.1038/nnano.2016.16810.1038/nnano.2016.168 ↗
29. 10.1016/j.jcis.2022.08.18610.1016/j.jcis.2022.08.186 ↗
30. 10.1126/sciadv.adk320110.1126/sciadv.adk3201 ↗
31. 10.1016/j.apsb.2022.02.02510.1016/j.apsb.2022.02.025 ↗
32. 10.20517/cdr.2020.5510.20517/cdr.2020.55 ↗
33. 10.1186/s12951-021-01082-110.1186/s12951-021-01082-1 ↗
34. 10.3390/ijms2308415310.3390/ijms23084153 ↗
35. 10.1186/s40824-021-00246-210.1186/s40824-021-00246-2 ↗
36. 10.1186/s13045-021-01103-410.1186/s13045-021-01103-4 ↗
37. 10.1016/j.matdes.2020.10938810.1016/j.matdes.2020.109388 ↗
38. 10.1038/s41565-019-0380-710.1038/s41565-019-0380-7 ↗
39. 10.7150/thno.3756810.7150/thno.37568 ↗
40. 10.1038/s41563-019-0566-210.1038/s41563-019-0566-2 ↗
41. 10.1038/nbt.333010.1038/nbt.3330 ↗
42. 10.3390/cancers1210289210.3390/cancers12102892 ↗
43. 10.1158/0008-5472.CAN-12-305610.1158/0008-5472.CAN-12-3056 ↗
44. 10.1371/journal.ppat.100668010.1371/journal.ppat.1006680 ↗
45. 10.3390/v1311217810.3390/v13112178 ↗
46. 10.1021/acs.molpharmaceut.1c0069810.1021/acs.molpharmaceut.1c00698 ↗
47. 10.1016/j.jconrel.2015.01.03910.1016/j.jconrel.2015.01.039 ↗
48. 10.1038/nnano.2017.5410.1038/nnano.2017.54 ↗
49. 10.1172/JCI6689510.1172/JCI66895 ↗
50. 10.1098/rsif.2012.093910.1098/rsif.2012.0939 ↗
51. 10.1021/acsnano.0c0667910.1021/acsnano.0c06679 ↗
52. 10.1016/j.bmt.2023.09.00110.1016/j.bmt.2023.09.001 ↗
53. 10.1210/en.2009-108210.1210/en.2009-1082 ↗
54. 10.1016/j.biopha.2016.08.06010.1016/j.biopha.2016.08.060 ↗
55. 10.1038/s41586-021-04243-210.1038/s41586-021-04243-2 ↗
56. 10.3389/fimmu.2017.0054410.3389/fimmu.2017.00544 ↗
57. 10.1515/aiht-2015-66-258210.1515/aiht-2015-66-2582 ↗
58. 10.3389/fimmu.2019.0013310.3389/fimmu.2019.00133 ↗
59. 10.3184/003685011X1297969734215110.3184/003685011X12979697342151 ↗
60. 10.1155/2015/14372010.1155/2015/143720 ↗
61. 10.1016/j.chempr.2016.07.00710.1016/j.chempr.2016.07.007 ↗
62. 10.3389/fbioe.2019.0000410.3389/fbioe.2019.00004 ↗
63. 10.3762/bjnano.5.17410.3762/bjnano.5.174 ↗
64. 10.1007/s11051-010-9911-810.1007/s11051-010-9911-8 ↗
65. 10.1371/journal.pone.009658410.1371/journal.pone.0096584 ↗
66. 10.1016/j.bbrep.2020.10074510.1016/j.bbrep.2020.100745 ↗
67. 10.1038/d41586-021-03806-710.1038/d41586-021-03806-7 ↗
68. 10.1038/s41467-018-05061-310.1038/s41467-018-05061-3 ↗
69. 10.1074/jbc.M110.12635910.1074/jbc.M110.126359 ↗
70. 10.1186/s12989-017-0199-z10.1186/s12989-017-0199-z ↗
71. 10.3389/fphar.2020.0096010.3389/fphar.2020.00960 ↗
72. 10.7150/ntno.3005210.7150/ntno.30052 ↗
73. 10.1038/s41536-023-00289-010.1038/s41536-023-00289-0 ↗
74. 10.1016/j.biomaterials.2019.02.02610.1016/j.biomaterials.2019.02.026 ↗
75. 10.1016/j.celrep.2021.10913110.1016/j.celrep.2021.109131 ↗
76. 10.1038/nbt.418110.1038/nbt.4181 ↗
77. 10.1038/s41565-018-0342-510.1038/s41565-018-0342-5 ↗
78. 10.1016/j.engreg.2020.06.00110.1016/j.engreg.2020.06.001 ↗
79. 10.1039/C9BM01643K10.1039/C9BM01643K ↗
80. 10.1039/C6CS00636A10.1039/C6CS00636A ↗
81. 10.2217/nnm.15.18810.2217/nnm.15.188 ↗
82. 10.1515/ntrev-2016-009810.1515/ntrev-2016-0098 ↗
83. 10.1021/acs.langmuir.5b0215810.1021/acs.langmuir.5b02158 ↗
84. 10.1016/j.jconrel.2016.01.01310.1016/j.jconrel.2016.01.013 ↗
85. 10.1016/j.msec.2016.09.01610.1016/j.msec.2016.09.016 ↗
86. 10.1039/C6NR08194K10.1039/C6NR08194K ↗
87. 10.3390/nano1111299110.3390/nano11112991 ↗
88. 10.1557/s43577-021-00132-110.1557/s43577-021-00132-1 ↗
89. 10.1016/j.cbi.2023.11053710.1016/j.cbi.2023.110537 ↗
90. 10.1021/acs.accounts.3c0011610.1021/acs.accounts.3c00116 ↗
91. 10.1039/C6RA08896A10.1039/C6RA08896A ↗
92. 10.3389/fchem.2014.0004810.3389/fchem.2014.00048 ↗
93. 10.1007/978-1-4939-9516-5_1610.1007/978-1-4939-9516-5_16 ↗
94. 10.1039/D1NR02065J10.1039/D1NR02065J ↗
95. 10.1557/adv.2019.48810.1557/adv.2019.488 ↗
96. 10.3390/cancers1105064010.3390/cancers11050640 ↗
97. 10.3390/ma1509325110.3390/ma15093251 ↗
98. 10.1016/j.nanoms.2021.12.00110.1016/j.nanoms.2021.12.001 ↗
99. 10.3390/ijms2123912310.3390/ijms21239123 ↗
100. 10.1002/btm2.1000510.1002/btm2.10005 ↗